Acceleron Pharma Inc (XLRN) : Novo As scooped up 12,800 additional shares in Acceleron Pharma Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 15, 2016. The investment management firm now holds a total of 685,863 shares of Acceleron Pharma Inc which is valued at $20,569,031.Acceleron Pharma Inc makes up approximately 2.10% of Novo As’s portfolio.
Other Hedge Funds, Including , Brown Brothers Harriman Co added XLRN to its portfolio by purchasing 471 company shares during the most recent quarter which is valued at $14,125. Blackrock Japan Ltd added XLRN to its portfolio by purchasing 94 company shares during the most recent quarter which is valued at $2,819.Blackrock Fund Advisors boosted its stake in XLRN in the latest quarter, The investment management firm added 57,968 additional shares and now holds a total of 1,128,078 shares of Acceleron Pharma Inc which is valued at $33,831,059. Acceleron Pharma Inc makes up approx 0.01% of Blackrock Fund Advisors’s portfolio.
Acceleron Pharma Inc opened for trading at $30.03 and hit $30.8 on the upside on Thursday, eventually ending the session at $30.25, with a gain of 0.80% or 0.24 points. The heightened volatility saw the trading volume jump to 1,35,679 shares. Company has a market cap of $1,137 M.
On the company’s financial health, Acceleron Pharma Inc reported $-0.59 EPS for the quarter, missing the analyst consensus estimate by $ -0.07 based on the information available during the earnings call on Aug 4, 2016. Analyst had a consensus of $-0.52. The company had revenue of $3.20 million for the quarter, compared to analysts expectations of $3.66 million. The company’s revenue was down -43.9 % compared to the same quarter last year.
Acceleron Pharma Inc. is a biopharmaceutical company focused on the discovery development and commercialization of therapeutic candidates that are based on the mechanisms that the human body uses to regulate the growth and repair of its cells and tissues. The Company’s research focuses on key natural regulators of cellular growth and repair particularly the Transforming Growth Factor-Beta (TGF-b) protein superfamily. By combining its discovery and development know-how including its knowledge of the TGF-b superfamily and its internal protein engineering and manufacturing capabilities the Company has built a discovery and development platform that has generated therapeutic candidates with new mechanisms of action. The Company has four internally discovered therapeutic candidates that are in clinical trials.